Press Releases

Date Title and Summary View
June 4, 2018 Sesen Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced the closing of its previously-announced public offering of 25,555,556 shares of
View HTML
May 31, 2018 Sesen Bio Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 30, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced the pricing of an underwritten public offering of 22,222,223 shares of its
View HTML
May 30, 2018 Sesen Bio Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 30, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its
View HTML
May 29, 2018 Sesen Bio to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of Sesen Bio , will
View HTML
May 21, 2018 Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients
Sesen Bio (Formally Eleven Biotherapeutics) Reports Positive, Three-Month Data from VISTA Trial of Vicinium™ in High-Grade NMIBC Data Presented During Plenary Session at American Urological Association Annual Meeting Company to Host Conference Call Today at 4:05 p.m. ET CAMBRIDGE, Mass.
View HTML
May 16, 2018 Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio
Name Change Reflects Company’s Focus on Late-Stage Oncology Drug Development Appointments of Senior Medical Advisor and Vice President of Regulatory Affairs Strengthen Leadership Team as Company Prepares for Phase 3 Three-month NMIBC Data CAMBRIDGE, Mass.
View HTML
May 15, 2018 Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates
Company to Host Conference Call in Conjunction with AUA Presentation on May 21, 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of
View HTML
April 12, 2018 New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 12, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that preclinical data from the company’s novel,
View HTML
April 4, 2018 Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to be Presented During Plenary Session at American Urological Association Annual Meeting; Company to Host Conference Call in Conjunction with Data Presentation in May 2018 Expected Operating Runway Extended into the First Quarter of 2019
View HTML
April 3, 2018 Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting
Eleven Biotherapeutics to Host Conference Call in Conjunction with Data Presentation in May CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the
View HTML